Search
VaxSyn
go.drugbank.com/drugs/DB17827InvestigationalVaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalDeveloped by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
NV-18
go.drugbank.com/drugs/DB05886ExperimentalLike phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalIt is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalSince January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer
Gentian violet cation
go.drugbank.com/drugs/DB00406ApprovedA dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Dopamine
go.drugbank.com/drugs/DB00988ApprovedInvestigationalOne of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regu...
Methoxamine
go.drugbank.com/drugs/DB00723ApprovedInvestigationalWithdrawnAn alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalIt is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.